Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

NCT00358176 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1231

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis Postmenopausal

Interventions

DRUG: Risedronate (HMR4003)

Sponsor

Sanofi

Collaborators

[object Object]